|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMX2 |
Gene summary for TMX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMX2 | Gene ID | 51075 |
| Gene name | thioredoxin related transmembrane protein 2 | |
| Gene Alias | CGI-31 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | Q9Y320 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51075 | TMX2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.06e-10 | 2.08e-01 | 0.0155 |
| 51075 | TMX2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.90e-11 | 3.00e-01 | -0.1808 |
| 51075 | TMX2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.00e-12 | 3.82e-01 | -0.0811 |
| 51075 | TMX2 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.86e-16 | 4.42e-01 | -0.1088 |
| 51075 | TMX2 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.41e-38 | 6.42e-01 | -0.1954 |
| 51075 | TMX2 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.20e-07 | 5.05e-01 | -0.2602 |
| 51075 | TMX2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.50e-04 | 3.37e-01 | -0.2196 |
| 51075 | TMX2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.03e-08 | 3.09e-01 | -0.1207 |
| 51075 | TMX2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.71e-21 | 5.64e-01 | -0.1526 |
| 51075 | TMX2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.92e-23 | 4.31e-01 | -0.1464 |
| 51075 | TMX2 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.93e-21 | 3.77e-01 | -0.1001 |
| 51075 | TMX2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.12e-26 | 6.11e-01 | -0.059 |
| 51075 | TMX2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.14e-07 | 4.65e-01 | -0.1706 |
| 51075 | TMX2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.52e-06 | 2.80e-01 | -0.2061 |
| 51075 | TMX2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.22e-05 | 3.63e-01 | -0.1462 |
| 51075 | TMX2 | HTA11_546_2000001011 | Human | Colorectum | AD | 6.66e-12 | 4.68e-01 | -0.0842 |
| 51075 | TMX2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.08e-04 | 2.52e-01 | -0.0179 |
| 51075 | TMX2 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.29e-15 | 3.30e-01 | 0.096 |
| 51075 | TMX2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.34e-04 | 3.36e-01 | 0.0446 |
| 51075 | TMX2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.58e-09 | 4.07e-01 | 0.0131 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMX2 | insertion | In_Frame_Ins | novel | c.184_185insCTTTGGTTGAATTCA | p.Asp62delinsAlaLeuValGluPheAsn | p.D62delinsALVEFN | Q9Y320 | protein_coding | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| TMX2 | SNV | Missense_Mutation | novel | c.85N>G | p.Ser29Ala | p.S29A | Q9Y320 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-AA-3855-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TMX2 | SNV | Missense_Mutation | c.486N>A | p.Phe162Leu | p.F162L | Q9Y320 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| TMX2 | SNV | Missense_Mutation | c.758N>A | p.Arg253Gln | p.R253Q | Q9Y320 | protein_coding | tolerated(0.18) | probably_damaging(0.974) | TCGA-DM-A282-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMX2 | SNV | Missense_Mutation | c.518N>G | p.Phe173Cys | p.F173C | Q9Y320 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMX2 | SNV | Missense_Mutation | novel | c.367N>A | p.Phe123Ile | p.F123I | Q9Y320 | protein_coding | tolerated(0.17) | benign(0.03) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TMX2 | SNV | Missense_Mutation | rs778852347 | c.787N>T | p.Arg263Trp | p.R263W | Q9Y320 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMX2 | SNV | Missense_Mutation | novel | c.92N>C | p.Leu31Pro | p.L31P | Q9Y320 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| TMX2 | SNV | Missense_Mutation | c.148N>T | p.Pro50Ser | p.P50S | Q9Y320 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMX2 | SNV | Missense_Mutation | rs757544083 | c.593N>A | p.Arg198His | p.R198H | Q9Y320 | protein_coding | deleterious(0.02) | benign(0.219) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51075 | TMX2 | THIOREDOXIN, DRUGGABLE GENOME | ethanol | ALCOHOL | 32451486 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |